Table 2 Characteristics of JIA pes planovalgus patients (JIA-PPV)
JIA-PPV | ||||
|---|---|---|---|---|
Parameter | n | Median | Q25/Q75 | |
JIA sub-types | ||||
Systemic arthritis | 2 | - | - | |
Persistent oligoarthritis | 2 | - | - | |
Extended oligoarthritis | 4 | - | - | |
Polyarthritis (RF neg.) | 2 | - | - | |
Enthesitis-related arthritis | 1 | - | - | |
JIA affected joints of the lower extremities | ||||
Hip left/right | 5/4 | - | - | |
Knee left/right | 9/9 | - | - | |
Ankle left/right | 10/10 | - | - | |
Midfoot left/right | 3/3 | - | - | |
Toe left/right | 3/2 | - | - | |
Drugs | ||||
Non-steroidal anti-inflammatory drugs | 4 | - | - | |
Disease-modifying anti-rheumatic drugs | 9 | - | - | |
Biologicals | 7 | - | - | |
Physician global assessment of overall disease activity (VAS 0-10 cm) | 11 | 4.1 | 0.9/7.1 | |
Duration of disease (y) | 11 | 7.5 | 5.6/10.7 | |
Pain intensity (VAS 0-10 cm) | 11 | 1.5 | 0.0/1.6 | |